secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2023-04-26T23:59:59+00:00
Accession:  0000917520-23-000026
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra LifeSciences Q1 revenue $380.8M, organic growth 4.6%; adj EPS $0.74 flat YoY
--------------------------------------------------------------------------------

- Q1 revenues $380.8M, +1.1% reported, +4.6% organic vs Q1 2022.
- GAAP EPS $0.29 vs $0.39 prior year; adjusted EPS $0.74 flat.
- Codman Specialty Surgical $248.1M (+3.5% organic); Tissue Technologies $132.7M (+6.8% organic).
- Full-year 2023 guidance reaffirmed: revenue $1,602-1,620M, adj EPS $3.43-3.51.
- Initiated $150M accelerated share repurchase; amended credit facility extended to 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752023000026/0000917520-23-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752023000026/iart-20230426.htm
  HTML page:      https://secwatch.observer/filing/0000917520-23-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer